Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)

Parkinson's Disease Clinical Trial

Official title:

Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02922530
• Other study ID #: PSC-1010-16
• Status: Withdrawn
• Phase: N/A
• First received: September 29, 2016
• Last updated: February 21, 2017
• Start date: November 2016
• Est. completion date: February 2017

Study information

• Verified date: February 2017
• Source: Posit Science Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of this research proposal is to develop an adjunct to standard treatments that 'correct' disrupted neural circuitry in Parkinson's Disease (PD) patients. Directly treating these core deficits via targeted behavioral training should slow the progression of PD, assure greater resilience against future decline, and improve the quality of life of many living with PD. The purpose of this exploratory research study is to determine the benefits, if any, of the mobile device-based treatment described above in individuals with PD.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Participants must meet diagnostic criteria for Parkinson's Disease with mild-to-moderate stage

• Participants must be fluent English speakers

• Participants must have the capability of completing the study as assessed by intact global cognition

• Participants must be able to engage with computerized cognitive tasks as required in the study

• Participants must have normal vision (or corrected to normal vision)

• Participants must have adequate hearing acuity

• Participants must have the motor capacity to use an iPad or mobile device

• Participants must be willing to commit to the time requirements of the study

• Participants must obtain benefit on dopaminergic treatment (dopamine agonist or levodopa) and be on a stable dose for at least one month prior to screening

• Participant must have access to wireless internet connectivity

• Participant must have at least mild depression as assessed by Beck Depression Inventory (BDI-II)

Exclusion Criteria:

• Participants who are unable to perform neuropsychological assessments in the opinion of the evaluating staff person

• Participants who cannot comprehend or follow instructions, in the opinion of the consenting staff person

• Participants who are not capable of giving informed consent, in the opinion of the consenting staff person

• Participants who show signs of intoxication due to current substance abuse (including alcohol and/or illegal drugs) during any in person visit

• Participants with history of significant medical diseases or multiple neurological events of the head

• Participants with serious or unstable medical illness

• Participants with history or current diagnosis of the following Diagnostic and Statistical Manual of Mental Disorders (DSM-5) psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder not otherwise specific, bipolar disorder, substance dependence, substance abuse (< 1 year) (subjects with co-occurring post-traumatic stress disorder and related disorders are eligible for participation) as diagnosed through medical history

• Participants with history of seizure disorder

• Participants who are pregnant

• Participants who experience frequent falls (several times a week)

• Participants with severe dyskinesia

• Participants with active suicidal ideations or behaviors as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

• Participants enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment that could affect the outcome of this study

• Participant is using computer-based cognitive training programs or has used it within a month of the consent date

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Other:
• Computerized Plasticity-based Adaptive Cognitive Training

• Commercially available computerized training

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Posit Science Corporation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change scores for depressive symptoms using Beck Depression Scale (BDI-II)		At 3 months and 6 months
Primary	Change scores for Quality of Life using Parkinson's Disease Questionnaire (PDQ-39)		At 3 months and 6 months